Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
78.64 USD | -0.07% |
|
+6.02% | +9.65% |
07-09 | RBC Raises Price Target on Intra-Cellular Therapies to $107 From $103, Keeps Outperform Rating | MT |
07-01 | Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) added to Russell 1000 Dynamic Index | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.65% | 8.31B | |
+7.40% | 101B | |
+8.42% | 42.18B | |
-13.29% | 32.26B | |
+80.80% | 29.79B | |
-11.63% | 16.06B | |
+1.85% | 14.45B | |
-6.77% | 12.01B | |
+177.16% | 10.71B | |
+4.12% | 8.89B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- RBC Raises Price Target on Intra-Cellular Therapies to $107 From $103, Keeps Outperform Rating